Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitors renal side effects and management.
Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M. Rassy EE, et al. Among authors: karak fe. Immunotherapy. 2016 Dec;8(12):1417-1425. doi: 10.2217/imt-2016-0099. Immunotherapy. 2016. PMID: 28000536 Review.
TRK inhibition in soft tissue sarcomas: A comprehensive review.
Assi T, Rassy E, Nassereddine H, Farhat F, Karak FE, Kattan J, Ghosn M. Assi T, et al. Among authors: karak fe. Semin Oncol. 2020 Feb;47(1):73-84. doi: 10.1053/j.seminoncol.2020.02.009. Epub 2020 Mar 9. Semin Oncol. 2020. PMID: 32201016 Review.
Should we screen patients with hematologic malignancies for COVID-19?
Rassy E, Khoury-Abboud RM, Ibrahim N, Assi T, Samra B, Hanna C, Karak FE, Ghosn M. Rassy E, et al. Among authors: karak fe. Hematol Oncol. 2020 Dec;38(5):648-653. doi: 10.1002/hon.2780. Epub 2020 Aug 8. Hematol Oncol. 2020. PMID: 32779823 Free PMC article. Review.
Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA, Sayed RE, Alameh IA, Khoury J, Nakib CE, Zerdan MB, Charafeddine M, Farhat F, Karak FE, Assi HI. Halim NA, et al. Among authors: karak fe. Cancer Treat Res Commun. 2021;26:100275. doi: 10.1016/j.ctarc.2020.100275. Epub 2020 Dec 11. Cancer Treat Res Commun. 2021. PMID: 33340905 Free article.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
21 results